Our data demonstrated an anti-inflammatory action on tumor cells due to the association of CrataBL and its related peptides with vemurafenib because NO production was significantly reduced, as well as the inflammatory cytokines IL-6 (30%, 24 h), IL-8, and PDGF-AB/BB. This evidence concerns the gene IL6 and neoplasm.